The New York University Cancer Institute (NYUCI) is seeking funding for its 26th year as an NCI-designated cancer center following a significant re-vitalization of cancer research and treatment activities on the NYU Medical Center campuses that was initiated in 1998. With the recruitment of Dr. Steven Burakoff in 2000 the NYUCI has undergone major expansion. Growth in facilities, faculty recruitment, research productivity, and clinical care has exceeded the benchmarks outlined in strategic plan articulated in the 2002 renewal. During the last funding period, twenty-four faculty in basic, translational and clinical research have been recruited to the NYUCI. Facilities to house research and treatment programs have expanded 400% with the opening the new NYU Clinical Cancer Center and the NYUCI Research Laboratories located within the new Smilow Research Center. Extramural funding has doubled to $64,087,423 (total) in peer reviewed funding and a overall research base of $75,898,561. Funding from the NCI has also doubled and now totals $19,750,445. The Cancer Center Support Grant (CCSG) builds on many unique institutional strengths of this metropolitan hospital center with a highly diverse faculty, staff and patient population. In the current application seven scientific programs are presented for consideration: Cancer Immunology and Immunotherapy, Growth Control, Cancer Stem Cells, Molecular and Environmental Carcinogenesis, Melanoma, Breast Cancer and Genitourinary Cancer. Ten shared resources are supported by the CCSG and two new cores, Vaccine and Cancer Genomics, are presented in the application. The Clinical Trials Office has supported the growth of NYU investigator-initiated studies which now account for 68.7% of all therapeutic accruals. Overall accruals have increased steadily over the past three years from 9.25% in 2004 to 13.3% (projected) in 2006. The NYUCI has fostered an environment that promotes research collaborations and multidisciplinary patient care with 24% of all publications being intra- or interprogrammatic (12% each). The CCSG application continues to be actively supported by the President of NYU, the Dean and CEO of NYU Medical Center, and Hospital and Community leadership who pledge additional resources.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016087-30
Application #
7777371
Study Section
Subcommittee G - Education (NCI)
Program Officer
Silkensen, Shannon M
Project Start
1996-12-01
Project End
2013-02-28
Budget Start
2010-03-01
Budget End
2011-02-28
Support Year
30
Fiscal Year
2010
Total Cost
$2,644,237
Indirect Cost
Name
New York University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
121911077
City
New York
State
NY
Country
United States
Zip Code
10016
Huang, Chao; Zeng, Xingruo; Jiang, Guosong et al. (2017) XIAP BIR domain suppresses miR-200a expression and subsequently promotes EGFR protein translation and anchorage-independent growth of bladder cancer cell. J Hematol Oncol 10:6
Silvera, Deborah; Ernlund, Amanda; Arju, Rezina et al. (2017) mTORC1 and -2 Coordinate Transcriptional and Translational Reprogramming in Resistance to DNA Damage and Replicative Stress in Breast Cancer Cells. Mol Cell Biol 37:
Koh, Hyunwook; Blaser, Martin J; Li, Huilin (2017) A powerful microbiome-based association test and a microbial taxa discovery framework for comprehensive association mapping. Microbiome 5:45
Ma, Lijie; Liu, Yan; Landry, Nichole K et al. (2017) Point mutation in D8C domain of Tamm-Horsfall protein/uromodulin in transgenic mice causes progressive renal damage and hyperuricemia. PLoS One 12:e0186769
Morabito, Michael V; Ravussin, Yann; Mueller, Bridget R et al. (2017) Weight Perturbation Alters Leptin Signal Transduction in a Region-Specific Manner throughout the Brain. PLoS One 12:e0168226
Koetz-Ploch, Lisa; Hanniford, Douglas; Dolgalev, Igor et al. (2017) MicroRNA-125a promotes resistance to BRAF inhibitors through suppression of the intrinsic apoptotic pathway. Pigment Cell Melanoma Res 30:328-338
Feig, Jessica L; Mediero, Aranzazu; Corciulo, Carmen et al. (2017) The antiviral drug tenofovir, an inhibitor of Pannexin-1-mediated ATP release, prevents liver and skin fibrosis by downregulating adenosine levels in the liver and skin. PLoS One 12:e0188135
Ono, Kentaro; Viet, Chi T; Ye, Yi et al. (2017) Cutaneous pigmentation modulates skin sensitivity via tyrosinase-dependent dopaminergic signalling. Sci Rep 7:9181
Wang, Xing; Zhang, Fenglin; Wu, Xue-Ru (2017) Inhibition of Pyruvate Kinase M2 Markedly Reduces Chemoresistance of Advanced Bladder Cancer to Cisplatin. Sci Rep 7:45983
Garré, Juan Mauricio; Silva, Hernandez Moura; Lafaille, Juan J et al. (2017) CX3CR1+ monocytes modulate learning and learning-dependent dendritic spine remodeling via TNF-?. Nat Med 23:714-722

Showing the most recent 10 out of 1082 publications